Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Creative Commons License

Koh C., Canini L., Dahari H., Zhao X., Uprichard S. L., Haynes-Williams V., ...Daha Fazla

LANCET INFECTIOUS DISEASES, cilt.15, sa.10, ss.1167-1174, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 10
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/s1473-3099(15)00074-2
  • Dergi Adı: LANCET INFECTIOUS DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1167-1174
  • Ankara Üniversitesi Adresli: Evet

Özet

Background Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory. Prenylation is essential for HDV and inhibition abrogates HDV production in experimental models. In a proof-of-concept study, we aimed to assess the effect on HDV RNA levels, safety, and tolerability of the prenylation inhibitor lonafarnib in patients with chronic delta hepatitis.'